ASX: IPD

01 July 2015

ASX ANNOUNCEMENT

Multi-disciplinary Centre Now in US Commercial L-Dex® Pilot Program

Brisbane, Australia – **ImpediMed Limited** (ASX: IPD) ("the Company"), is pleased to announce the launch of an additional L-Dex pilot with a prominent multi-specialty health care organisation in the US. This is the fifth of six planned cancer centre pilots.

Previous pilot participants were major oncology centres. This pilot involves a multi-disciplinary health care organisation comprised of five hospitals and more than 100 outpatient clinics. Being accredited by both the Commission on Cancer of the American College of Surgeons, as well as the Commission on Accreditation of Rehabilitation Facilities, they provide patient coverage from cancer diagnosis to treatment and on through survivorship.

"I am very pleased that we have expanded the cancer centre pilot program for L-Dex to this multi-disciplinary, Joint Commission accredited organisation", stated Managing Director and CEO Richard Carreon. "The Joint Commission accredits and certifies only those health care organisations which reflect a commitment to meeting the highest standards of care in the US. Moving beyond the community oncology centres allows L-Dex to be fully integrated into the complete patient care continuum to maximise the benefit to cancer patients."

The pilot program activities include integrating a prospective surveillance model for the early detection of cancer related lymphoedema using L-Dex, capturing L-Dex scores in the electronic medical records (EMR), and providing education and training for staff, patients, and referring physicians. This multi-disciplinary pilot program will offer us additional vital insight into our market for the full commercial launch of L-Dex in the US, which is scheduled for later in calendar year 2015.

Richard Carreon
Managing Director & CEO

For further information contact:
Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Kyahn Williamson, Buchan
Investor and Media Relations
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus

improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au